Advertisement
ABT vs ALC
Which Stock Would AI Choose? Abbott Laboratories (ABT) vs. Alcon (ALC) Stock Comparison
Key Takeaways
- Different healthcare niches: ABT is a diversified healthcare conglomerate spanning nutrition, diagnostics, medical devices, and pharmaceuticals, while ALC is a pure-play eye-care specialist in surgical equipment and vision care.
- Scale gap: Abbott's market capitalization is roughly five times larger than Alcon's, reflecting a broader revenue base but also greater exposure to multiple segment cycles.
- Growth vs. profitability tension: Both companies have posted solid revenue growth recently, yet each has also faced margin and earnings pressures that have weighed on sentiment.
- Diverging catalysts: Abbott's Exact Sciences acquisition and new product approvals contrast with Alcon's product launch cadence, buybacks, and tariff exposure.
- Similar technical backdrop: Both stocks have declined materially over the past year, making relative momentum and stability key differentiators for AI-driven screening.
Introduction
Abbott Laboratories and Alcon operate in adjacent corners of healthcare but serve investors with very different profiles. Abbott is a diversified medical technology and healthcare giant whose devices, diagnostics, nutrition, and branded generics businesses span the globe. Alcon, spun off from Novartis in 2019, is a focused leader in eye care, including surgical equipment, intraocular lenses, contact lenses, and dry-eye treatments. This stock comparison is relevant for traders and investors weighing broad diversification against concentrated exposure to a single high-demand specialty. By examining recent market activity, growth drivers, and risk factors, this analysis clarifies how each name's market positioning and relative performance compare in the current environment.
ABT Overview and Recent Performance
ABT has been navigating a period of strategic repositioning even as its shares have come under pressure. The company's recent market activity has been shaped by the March 2026 completion of its acquisition of Exact Sciences, a cancer-diagnostics firm behind the Cologuard colorectal screening test. That deal added a high-growth Cancer Diagnostics segment to Abbott's portfolio but also introduced near-term earnings dilution, prompting management to update full-year adjusted earnings guidance to a range of roughly $5.38 to $5.58 per share while maintaining comparable sales growth expectations in the mid-to-high single digits.
Recent quarterly results reflect a familiar tension: revenue has expanded, yet reported net income and earnings per share have declined, a pattern analysts attribute to cost pressures, legal expenses, and integration-related items. On the product front, Abbott has received U.S. Food and Drug Administration (FDA) approval for its TactiFlex Duo ablation catheter for treating atrial fibrillation, and it has launched new nutrition and diagnostics offerings. Despite these catalysts, the stock has slid significantly over the past year, with some analysts upgrading the name on valuation grounds while others point to ongoing litigation overhang in its Nutrition segment. The result is a mixed sentiment backdrop in which robust top-line momentum coexists with persistent profitability concerns.
ALC Overview and Recent Performance
ALC has focused on refreshing its product pipeline across both of its segments — Surgical and Vision Care — while managing a softer cataract procedure market and evolving trade policy. Recent quarters have featured accelerating revenue growth driven by new launches, including the Unity equipment platform, the PanOptix Pro intraocular lens, the TOTAL30 contact-lens family, and dry-eye products such as Tryptyr and Systane. The company has also raised its 2026 profitability outlook, lifting core earnings-per-share growth guidance, and has executed a sizable share buyback program.
At the same time, Alcon faces headwinds that have pressured relative performance. U.S. import tariffs have created a measurable cost drag, with management citing a net tariff impact in the range of roughly $100 million to $150 million for the year. Implantables revenue has been constrained by competitive pressure in international markets and soft surgical-glaucoma sales, while cataract procedure volumes have grown only modestly. Alcon also abandoned its planned acquisition of Lensar earlier in 2026. The stock has declined over the past year, reflecting the combined weight of these factors despite improving fundamentals in several product lines.
Trending AI Robots
For traders seeking a systematic edge, Tickeron's Trending AI Robots page curates a focused selection from a much larger universe of AI trading bots that collectively trade thousands of different tickers. Tickeron offers hundreds of these bots — more than 300 in total — but only a relative handful are highlighted in the Trending section at any given time, chosen for their suitability to current market conditions. The featured bots span a wide range of trading styles, strategies, timeframes, and ticker sets, with published statistics such as realized returns, win rates, profit factors, average trade duration, and profit-to-drawdown ratios. Because each bot is built for different objectives and holding periods, reviewing their individual performance metrics can help traders match a strategy to their own risk tolerance. Explore the Trending AI Robots page to see which strategies are currently leading.
Head-to-Head Comparison
The core contrast between ABT and ALC lies in business structure and exposure. Abbott's diversification across four major segments reduces reliance on any single end-market but also means one segment's weakness — such as Nutrition's recent volume declines or litigation costs — can offset strength elsewhere. Alcon, by contrast, offers concentrated exposure to eye care, a structurally growing category driven by aging demographics, yet it is more sensitive to procedure-volume trends and trade policy in any given quarter.
On growth drivers, Abbott leans on the Exact Sciences integration, an expanding electrophysiology portfolio, and emerging-market branded generics. Alcon relies on a steady cadence of equipment, lens, and dry-eye launches. On risk factors, Abbott's key overhangs are litigation, acquisition dilution, and margin compression, while Alcon's are tariffs, competitive pressure in implantables, and soft cataract demand. Market sentiment toward both names has been cautious, but the quality of catalysts differs: Abbott's are largely structural and portfolio-shaping, whereas Alcon's are more operational and product-led.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, a probabilistic AI assessment would likely tilt slightly toward ALC in the current environment. Alcon's recently raised profitability guidance, visible product-launch pipeline, and active capital-return program offer a steadier, more clearly defined near-term narrative, even as tariffs and procedure softness temper the outlook. Abbott's scale and diversification are strengths, but its recent earnings compression, litigation overhang, and integration complexity introduce more mixed signals. This is a relative, not absolute, judgment: both stocks currently exhibit weak price momentum, and the preference reflects Alcon's comparatively clearer operating catalysts rather than a claim of guaranteed outperformance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABT is a Hold and ALC is a StrongBuy.
ABT in +2.49% Uptrend, rising for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABT advanced for three days, in 172 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABT's RSI Indicator exited the oversold zone, 18 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 49%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on ABT as a result. In 46 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for ABT just turned positive on October 09, 2026. Looking at past instances where ABT's MACD turned positive, the stock continued to rise in 25 of 54 cases over the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 54 cases where ABT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ABT broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ABT entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.403) is normal, around the industry mean (2.874). P/E Ratio (32.423) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.052). Dividend Yield (0.025) settles around the average of (0.009) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ALC in upward trend: price rose above 50-day moving average on October 22, 2026
ALC moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 23 of 33 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ALC as a result. In 61 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for ALC just turned positive on October 09, 2026. Looking at past instances where ALC's MACD turned positive, the stock continued to rise in 28 of 53 cases over the following month. The odds of a continued upward trend are 53%.
Following a +5.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALC advanced for three days, in 181 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ALC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALC entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. ALC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.509) is normal, around the industry mean (4.961). P/E Ratio (51.083) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (1.165) is also within normal values, averaging (4.143). Dividend Yield (0.015) settles around the average of (0.005) among similar stocks. P/S Ratio (2.996) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ABT | ALC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 68 | 88 | |
PRICE GROWTH RATING 1..100 | 55 | 56 | |
P/E GROWTH RATING 1..100 | 5 | 10 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALC's Valuation (69) in the Hospital Or Nursing Management industry is in the same range as ABT (70) in the Medical Specialties industry. This means that ALC’s stock grew similarly to ABT’s over the last 12 months.
ALC's Profit vs Risk Rating (100) in the Hospital Or Nursing Management industry is in the same range as ABT (100) in the Medical Specialties industry. This means that ALC’s stock grew similarly to ABT’s over the last 12 months.
ABT's SMR Rating (68) in the Medical Specialties industry is in the same range as ALC (88) in the Hospital Or Nursing Management industry. This means that ABT’s stock grew similarly to ALC’s over the last 12 months.
ABT's Price Growth Rating (55) in the Medical Specialties industry is in the same range as ALC (56) in the Hospital Or Nursing Management industry. This means that ABT’s stock grew similarly to ALC’s over the last 12 months.
ABT's P/E Growth Rating (5) in the Medical Specialties industry is in the same range as ALC (10) in the Hospital Or Nursing Management industry. This means that ABT’s stock grew similarly to ALC’s over the last 12 months.
| ABT | ALC | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 49% | 1 day ago 71% |
| Stochastic ODDS (%) | 1 day ago 52% | 1 day ago 49% |
| Momentum ODDS (%) | 1 day ago 53% | 1 day ago 67% |
| MACD ODDS (%) | 1 day ago 46% | 1 day ago 53% |
| TrendWeek ODDS (%) | 1 day ago 54% | 1 day ago 58% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 57% |
| Advances ODDS (%) | 7 days ago 56% | 8 days ago 57% |
| Declines ODDS (%) | 2 days ago 56% | 4 days ago 56% |
| BollingerBands ODDS (%) | 1 day ago 55% | 1 day ago 66% |
| Aroon ODDS (%) | 1 day ago 50% | 1 day ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABT’s FA Score shows that 1 FA rating(s) are green while ALC’s FA Score has 1 green FA rating(s).
- ABT’s FA Score: 1 green, 4 red.
- ALC’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABT’s TA Score shows that 4 TA indicator(s) are bullish while ALC’s TA Score has 4 bullish TA indicator(s).
- ABT’s TA Score: 4 bullish, 4 bearish.
- ALC’s TA Score: 4 bullish, 4 bearish.
Price Growth
ABT (@Medical/Nursing Services) experienced а -2.07% price change this week, while ALC (@Pharmaceuticals: Other) price change was +6.08% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.59%. For the same industry, the average monthly price growth was -3.91%, and the average quarterly price growth was +7.47%.
Reported Earning Dates
ABT is expected to report earnings on Jan 27, 2027.
ALC is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+0.59% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
ALC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALC has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALC jumps, then SYK could also see price increases.